Filing Flows › Axsome Therapeutics (AXSM) › Q1 2025
Axsome Therapeutics (AXSM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Axsome Therapeutics (AXSM) reported revenue of $121M for the first quarter 2025 (Q1 2025), +62% from a year earlier and +2% from the quarter before. Operating margin was -46.9%, net loss $59.4M (48.9% of revenue).
Axsome Therapeutics, Q1 2025: revenue $121M (+62% year over year), operating margin -46.9%, net loss $59.4M, operating cash flow −$43.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121M | +2% | +62% |
| Operating profit | −$57.0M | — | — |
| Net earnings | −$59.4M | — | — |
| Operating cash flow | −$43.4M | — | — |
What changed
Revenue was $121.5M in Q1 2025, up 62% year over year and up 2% from the previous quarter. Product was the largest line at 99% of revenue. Product added $46.3M year over year (up 62%), 100% of the total change.
Operating costs exceeded revenue by $57.0M, an operating margin of -46.9%. Total costs grew 25% against revenue growth of 62%. The fastest-growing cost line was Cost of revenue (+55%). The quarter ended with a net loss of $59.4M, narrower than the previous quarter's $74.9M loss.
Operating cash flow was −$43.4M. Non-cash charges added back $1.7M of depreciation and amortization and $23.3M of share-based compensation. Working capital and other items used $9.0M. Capital expenditures of $338K exceeded it, leaving free cash flow of −$43.7M.
Questions
What was Axsome Therapeutics' revenue in the first quarter 2025?
Axsome Therapeutics (AXSM) reported revenue of $121M for the first quarter 2025 (Q1 2025), +62% from a year earlier and +2% from the quarter before.
Was Axsome Therapeutics profitable in the first quarter 2025?
Operating loss was $57.0M (-46.9% of revenue) and net loss $59.4M.